5NRA Stock Chart & Stats
€33.60
-€0.80(-2.38%)
At close: 4:00 PM EDT
€33.60
-€0.80(-2.38%)
Day’s Range― - ―
52-Week Range€5.70 - €47.40
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€1.71B
Enterprise Value€1.17K
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume5
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.81Price Target Upside-14.25% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.22
Revenue Forecast (FY)€35.79M
Bulls Say, Bears Say
Bulls Say
Intellectual Property & PlatformA broad patent estate across its nanotechnology platforms creates a durable barrier to entry, supporting exclusivity for delivery and radioenhancement approaches. This IP foundation underpins long-term licensing, partnership value and potential multi-indication extension beyond single assets.
Strategic Partnership & Regulatory MomentumAn FDA-accepted protocol amendment that shortens the event threshold can materially accelerate a pivotal readout and potential registration path. This strengthens the Janssen co-development channel and increases the likelihood of earlier milestone realization and regulatory clarity.
Extended Cash Runway / FundraisingA successful global equity raise that extends runway into 2029 materially reduces near-term refinancing risk, enabling multi-year development of Nanoprimer and ancillary platforms, supporting clinical programs and strategic partnering without immediate funding pressure.
Bears Say
Weakened Balance Sheet / LeverageNegative equity and elevated debt versus assets indicate weakened capitalization and higher leverage risk. This limits strategic flexibility, increases sensitivity to financing conditions, and raises the cost and constraints around partnering, M&A or commercialization investments.
Persistent Cash BurnConsistent negative operating and free cash flow shows the business remains cash consumptive despite revenue rebounds. Ongoing burn sustains dependence on external capital, which can dilute shareholders and force prioritization of programs rather than broad parallel development.
Early-Stage Clinical Evidence & Partner ReliancePromising signals from a seven-patient cohort are encouraging but remain preliminary; efficacy and safety must be confirmed in larger randomized studies. Heavy reliance on Janssen/MD Anderson for pivotal execution concentrates execution risk and limits Nanobiotix’s direct control over timelines.
5NRA FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was €5.70 and its highest was €47.40 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is €1.71B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Sep 30, 2026 which is in 58 days.
How were Nanobiotix’s earnings last quarter?
Currently, no data Available
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Overvalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,619,583 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in DE:5NRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Company Description
Nanobiotix
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
5NRA Company Deck
5NRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.View all DE:5NRA earnings summaries5NRA Stock 12 Month Forecast
Average Price Target
€28.81
▼(-14.25% Downside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―